A Bright Future for Photopharmaceuticals Addressing Central Nervous System Disorders: State of the Art and Challenges

Rudolf L Z Ganzoni1, Sofie S Bournons2, Erick M Carreira1

  • 1Laboratorium für Organische Chemie, Eidgenössische Technische Hochschule Zürich, Zürich, Switzerland.

PubMed

Insights

Photopharmacology uses light to precisely activate drugs for neurological disorders. While promising for central nervous system (CNS) diseases, further advancements in drug design and light delivery are needed for clinical translation.

Area of Science:

  • Neuroscience
  • Pharmacology
  • Biochemistry

Background:

  • Photopharmacology offers precise, localized drug activation, ideal for treating neurological disorders.
  • Current applications in human central nervous system (CNS) diseases are limited, requiring further development.

Purpose of the Study:

  • To review strategies for designing and activating photopharmaceutical agents in neuroscience.
  • To highlight photoactivatable compounds for modulating key neurotransmitter systems and managing pain.

Main Methods:

  • Discussion of photocaged and photoswitchable drugs and bioactive molecules.
  • Analysis of compound design strategies with illustrative examples.
  • Assessment of compounds with potential for clinical translation.

Main Results:

  • Overview of various photoactivatable compounds targeting glutamatergic, GABAergic, dopaminergic, and serotonergic systems.
  • Exploration of photoresponsive molecules for pain management.
  • Identification of promising compounds for clinical translation.

Conclusions:

  • Neurophotopharmaceuticals show great potential but require further maturity in light delivery and drug design.
  • This review provides a perspective on future opportunities in neurophotopharmacology for CNS disorders.